ViPOR’s Venom — Rationally Targeting DLBCL with Precision
Mené sur 20 puis 40 patients atteints d'un lymphome diffus à grandes cellules B réfractaire ou récidivant (durée médiane de suivi : 40 mois), cet essai de phase IB/2 détermine la dose maximale tolérée de vénétoclax en combinaison avec des doses fixes d'ibrutinib, de prednisone, d'obinutuzumab et de lénalidomide puis évalue la toxicité de cette combinaison
Large B-cell lymphoma (LBCL) spans the gamut of aggressive lymphoid tumors with extensive biologic and clinical heterogeneity. Most patients with LBCL are cured with the use of front-line chemoimmunotherapy, yet approximately 40% have a relapse.1 Although second-line CD19-targeted chimeric antigen receptor (CAR) T-cell therapy for persistent or early relapsing disease has improved outcomes, most patients with relapsed or refractory disease still ultimately succumb to lymphoma.2 Advances in our understanding of the molecular features of LBCL have led to hope that precision-medicine approaches targeting defined biologic pathways can meaningfully improve outcomes.1 Gene-expression profiling has divided diffuse LBCL (DLBCL) into two major . . .